Timeline
septiembre de 2015
Doctorado: MEDICINA
UCM
diciembre de 1990
Especialidad: MÉDICO ESPECIALISTA EN FARMACOLOGÍA CLÍNICA
MINISTERIO DE EDUCACION Y CIENCIA
enero de 1985
Titulado superior / Grado: LICENCIADO EN MEDICINA Y CIRUGÍA
UNIVERSITAT AUTòNOMA DE BARCELONA
Reconocimientos Docentes
Reconocimientos Investigación
Timeline
septiembre de 2018
Profesor Asociado Ciencias Salud LOU
Universidad Autónoma de Madrid. Farmacología
2018 - 2021
septiembre de 2017
Asociado Ciencias salud LOU (020020067). Farmacología
Universidad Autónoma de Madrid
2017 - 2019
enero de 2007
Investigadora Evaluadora/Panelista en proyectos de investigación convocatorias 2015, 2014,2 011 y 2007
Insituto de Salud Carlos III
2007 - 2015
septiembre de 2006
Member of the Management Board of the European Medicines Agency
European Medicines Agency (EMA)
2006 - 2010
enero de 2006
Directora de la Agencia del Medicamento
Agencia del Medicamento
2006 - 2010
enero de 2006
Directora de la Agencia del Medicamento
Agencia Espanola de Medicamentos y Productos Sanitarios
2006 - 2010
enero de 2004
Asociado CC salud LOU (020020067). Farmacología
Universidad Autónoma de Madrid
2004 - 2017
abril de 2002
Asociado CC. Salud LRU. Farmacología
Universidad Autónoma de Madrid
2002 - 2003
octubre de 2000
Asociado CC. Salud LRU. Medicina Preventiva y Salud Pública y Microbiología
Universidad Autónoma de Madrid
2000 - 2001
enero de 1999
Coordinadora de Evaluación clínica
Agencia Española del Medicamento
1999 - 2000
enero de 1999
Coordinadora de Evaluación clínica
Agencia Española del mediciamento
1999 - 2000
mayo de 1995
Member of several scientific Committees of the European Medicines Agency (Efficacy WP, CHMP,..)
European Medicines Agency (EMA)
1995 - 2006
enero de 1995
Médico Adjunto del Servicio de Farmacología Clínica
Hospital Universitario Puerta de Hierro
1995 - 1999
enero de 1986
Médico interno Residente en el Servicio de Farmacología
Hospital Universitario Marqués de Valdecilla
1986 - 1989
Publicaciones en Altmetrics
| 2020 | Early efficacy evaluation of mesenchymal stromal cells (MSC) combined to biomate... | |
| 2020 | Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia ... | |
| 2020 | A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatmen... | |
| 2019 | Low risk pragmatic trials do not always require participants' informed consent | |
| 2019 | Feasibility and safety of treating non-unions in tibia, femur and humerus with a... | |
| 2019 | Modifications and waivers of informed consent and the Council for International ... | |
| 2019 | A limited number of medicines pragmatic trials had potential for waived informed... | |
| 2019 | Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in ax... | |
| 2018 | A Multicentric, Open-Label, Randomized, Comparative Clinical Trial of Two Differ... | |
| 2018 | A randomized placebo controlled clinical trial to evaluate the efficacy and safe... | |
| 2018 | Knowledge about Biosimilars in Primary Care: A study by the Spanish Society of P... | |
| 2018 | Cervical pessary compared with vaginal progesterone for preventing early preterm... | |
| 2017 | Prevalence and Risk Factors of Prolonged Corrected QT Interval among Children an... | |
| 2017 | Should clinically meaningful outcomes in cancer be based on individual survival ... | |
| 2016 | Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General P... | |
| 2016 | Roundtable on biosimilars with European regulators and medical societies, Brusse... | |
| 2015 | Evaluation of dose reduction versus standard dosing for maintenance of remission... | |
| 2015 | Are Spanish Regions Implementing The National Therapeutic Positioning Report (Tp... | |
| 2015 | Evaluation of two treatment strategies for the prevention of preterm birth in wo... | |
| 2015 | Dose increase needed in most cystic fibrosis lung transplantation patients when ... | |
| 2014 | Regulatory authorities and orthopaedic clinical trials on expanded mesenchymal s... | |
| 2014 | SENTIA: a systematic online monitoring registry for children and adolescents tre... | |
| 2014 | Biosimilar therapy for inflammatory bowel disease | |
| 2014 | [Results from the 2012-2013 paediatric national survey on off-label drug use in ... | |
| 2013 | Drug utilization and off-label drug use in Spanish pediatric gastroenterology ou... | |
| 2012 | [Changes in the European normative of clinical trials (i): a chance to improve t... | |
| 2009 | [Compassionate use of off-label drugs: need for a change in Spain] | |
| 2008 | When should re-consent of subjects participating in a clinical trial be requeste... | |
| 2006 | Interferons: Types and actions | |
| 2005 | Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with c... | |
| 2004 | Expert consensus document on angiotensin converting enzyme inhibitors in cardiov... | |
| 2004 | Expert consensus document on beta-adrenergic receptor blockers: the Task Force o... | |
| 2003 | [Pharmacogenetic studies: evaluation guidelines for research ethics committees. ... | |
| 2003 | [Unified report from committes on Ethics and Clinical Investigations in multicen... | |
| 2003 | [Pharmacogenetic studies: evaluation guidelines for research ethics committees. ... | |
| 1997 | Digoxin in patients with heart failure |
Temáticas más frecuentes
Temáticas
Proyectos participados
Dirección y participación en proyectos
IP
NO IP
Grupos, Redes
Asignatura / Curso
Actividad docente
Tesis Dirigidas
1
Centros
Universidad Autónoma de Madrid
Colaboración institucional últimos 5 años
